Industrial Policy & Trade Monitor· 2662 actions· ✨ 89 recent

On 8 May 2026 China's National Health Commission released a public consultation draft proposing material amendments to the 2023 Implementation Rules for the Administrative Regulations on Human Genetic Resources, with a comment deadline of 7 June 2026. The draft narrows the statutory "foreign party" definition to a bright-line 50% equity/voting threshold (excluding VIE-structured entities), restricts "HGR Information" strictly to nucleic-acid sequence data (excluding clinical, imaging, and metabolic data), removes the separate Article 37 security-review requirement for sensitive HGR datasets, and introduces a same-day or next-working-day fast-track confirmation for international clinical trials not involving HGR information export.

The Office of the United States Trade Representative released the 2026 Special 301 Report on 30 April 2026, designating Vietnam as a Priority Foreign Country (PFC) — the most severe category under Section 182 of the Trade Act of 1974 (19 U.S.C. § 2242). This is the first PFC designation since Ukraine held the status from 2013 through 2015, a gap of approximately 11 years. The PFC designation triggers a statutory 30-day window (expiring ~30 May 2026) within which USTR must decide whether to initiate a Section 301 investigation under 19 U.S.C. § 2412(b)(2)(A), which could lead to tariffs, withdrawal of trade benefits, or other Section 301 enforcement remedies against Vietnam. Separately, the EU was added to the Watch List for the first time, citing AI training-data, geographical-indications, and customs-enforcement concerns.

On 26 April 2026, the UAE Cabinet, chaired by Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum, approved a four-part industrial-resilience package: (i) a National Industrial Resilience Fund with AED 1 billion (~USD 272m) capital managed by Emirates Development Bank over five years covering food industries, manufacturing, primary metals, mechanical/electrical/chemical industries, pharmaceuticals and medical supplies, advanced technology, and construction — designed to localise over 5,000 critical products and link confirmed procurement demand with targeted financing for local manufacturers; (ii) structural overhaul of the National In-Country Value (ICV) Programme, transitioning it from incentive-based to MANDATORY across federal entities and companies in which the government holds 25% or more; (iii) a National Product Retail Presence Policy strengthening visibility of UAE-manufactured goods in retail and digital channels (Phase 1: bottled water, dairy, eggs, poultry, bread, flour, vegetable oils, seasonal vegetables); and (iv) a National Industrial Data Committee chaired by Hasan Jassim Al Nowais (Undersecretary, MoIAT), with AI-driven forecasting and risk management integrated into industrial-resilience monitoring.

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

Premier Li Qiang signed State Council Order No. 834 on 31 March 2026 promulgating the "Provisions on Industrial Chain and Supply Chain Security" (18 articles), adopted at the State Council executive meeting on 13 March 2026 and effective on the date of publication. The Provisions are the first dedicated PRC administrative regulation on industrial- and supply-chain security and consolidate authorities drawn from the National Security Law, Foreign Relations Law, Anti-Foreign Sanctions Law, and Foreign Trade Law into a horizontal defensive framework. They establish a cross-agency coordination mechanism spanning roughly 15 central departments (industrial, security, cyberspace, customs and financial regulators) plus provincial governments; create a security-investigation system; and vest broad countermeasure authority over both foreign states (Article 14 — import/export prohibitions and special levies) and foreign organisations and individuals (Article 15 — import/export bans, China-investment bars, transaction prohibitions, entry bars and revocation of work or residence permits, with extension to effectively-controlled subsidiaries). The Provisions also impose compliance, information-sharing, strategic-reserve and emergency-response obligations on PRC organisations and individuals, and authorise requisition, mandated production and directed transportation in the event of supply-chain disruption.

On 1 May 2026 the trade pillar of the EU-Mercosur Partnership Agreement (the "Interim Trade Agreement", iTA) entered provisional application between the European Union and the four Mercosur states — Argentina, Brazil, Paraguay and Uruguay — following its publication in the EU Official Journal on 27 February 2026 alongside the broader EU-Mercosur Partnership Agreement (EMPA). The iTA covers goods (eliminating duties on more than 90% of bilateral trade over a transition period including immediate cuts on cars, pharmaceuticals, wine and olive oil), services, government procurement at federal and state level, intellectual property (344 EU geographical indications protected), SPS/TBT disciplines, and a sustainability chapter. Mercosur receives tariff-rate quotas on agri-food exports (beef, poultry, sugar, ethanol, honey). Provisional application proceeds pending full ratification of EMPA by the Council, European Parliament and all EU national parliaments and a pending CJEU opinion; only the trade pillar applies provisionally.

President Trump signed a Presidential Proclamation on 20 February 2026 invoking Section 122 of the Trade Act of 1974 (19 U.S.C. § 2132) to impose a temporary 10% ad-valorem import surcharge on articles imported into the United States, effective 12:01 a.m. EST on 24 February 2026. The proclamation was issued within hours of the US Supreme Court's 20 February 2026 ruling in Learning Resources, Inc. v. Trump, which held that the International Emergency Economic Powers Act (IEEPA) does not authorize the president to set tariffs and vacated the IEEPA-based reciprocal-tariff regime previously in effect. The Section 122 surcharge is statutorily limited to 150 days (terminates 24 July 2026 absent Congressional extension) and the statute caps any such surcharge at 15% ad valorem. Goods qualifying as USMCA originating from Canada or Mexico are exempt; CAFTA-DR textile/apparel articles meeting specified rules of origin are exempt; and a substantial product-exception list excludes critical minerals, energy products, certain pharmaceuticals, electronics, vehicles, aerospace products, specified agricultural goods, and goods already subject to Section 232 duties (the Section 122 duty does not stack on Section 232).

On 12 February 2026, Ambassador Jamieson Greer of the Office of the United States Trade Representative oversaw the signing of the US-Taiwan Agreement on Reciprocal Trade (ART) in Washington, DC. The instrument was signed under the auspices of the American Institute in Taiwan (AIT) and the Taipei Economic and Cultural Representative Office in the United States (TECRO). Headline terms: (i) US IEEPA reciprocal-tariff rate on Taiwan reduced from 20% to 15% and Section 232 auto-parts/timber/lumber rate cut from 25% to 15%; (ii) Taiwan eliminates or reduces 99% of its tariff barriers on US goods, most immediately and the remainder phased over three years; (iii) Taiwan side commits ~USD 85bn in directed purchases through 2029 (USD 44.4bn LNG/crude, USD 15.2bn civil aircraft and engines, USD 25.2bn power equipment); (iv) sectoral chapters covering tariffs, non-tariff barriers, digital trade, economic security, and high-tech supply-chain resilience. Operationally linked to the 15 January 2026 AIT-TECRO Memorandum of Understanding on investment, under which Taiwan pledges USD 250bn in direct Taiwanese-enterprise investment in the US plus USD 250bn in Taiwan-government credit guarantees (USD 500bn total) to fund US-side industrial parks/clusters in advanced semiconductors, energy, and AI manufacturing. Entry into force is conditional on Taiwan's Legislative Yuan completing its review.

On 9 February 2026 USTR Ambassador Jamieson Greer and Bangladesh Adviser Sheikh Bashir Uddin signed the Agreement on Reciprocal Trade (ART) between the United States and Bangladesh in Washington DC — USTR's first ART signing in South Asia, preceding the US-India interim-trade-framework finalisation by three days. The deal locks the US reciprocal tariff on Bangladesh-originating goods at 19% (down from 35% under the April 2025 IEEPA regime) and establishes a zero-percent mechanism for products on the Annex III aligned- partner list (EO 14346, 5 September 2025). Bangladesh commits to significant preferential market access for US industrial and agricultural goods — including chemicals, machinery, motor vehicles, medical devices, ICT equipment, energy products, soy, dairy, beef, poultry, tree nuts, and fruit — and to eliminating specified non- tariff barriers including acceptance of US Federal motor-vehicle safety and emissions standards, FDA certificates, and prior marketing authorisations for medical devices and pharmaceuticals.

On 6 February 2026 Presidents Trump and Modi announced a framework for an Interim Trade Agreement that resets the bilateral tariff posture installed in 2025. Two operative instruments: (i) an executive order signed 6 February eliminating, effective 7 February 2026, the additional 25% IEEPA "Russian-oil" duty on Indian imports imposed by EO 14329 (27 August 2025), conditional on India's commitment to cease buying Russian crude and to expand defence cooperation; and (ii) reduction of the EO 14257 reciprocal-tariff rate on India from 25% to 18% on listed product categories (textiles and apparel, leather and footwear, plastics and rubber, organic chemicals, home décor, artisanal products, certain machinery), to take effect on finalisation of the Interim Agreement. India commits to eliminate or reduce tariffs on all US industrial goods and a wide range of agricultural products (DDGs, red sorghum, tree nuts, fresh and processed fruit, soybean oil, wine, spirits) and to purchase >USD 500bn of US energy, ICT, coal, aircraft and aircraft parts, and precious-metals products over five years. The framework also commits the parties to negotiating "robust, ambitious, and mutually beneficial digital trade rules" and to addressing non-tariff barriers in medical devices, ICT import licensing, and food/agricultural standards. US tariff reductions on Indian generic pharmaceuticals, gems, diamonds, aircraft parts, and certain automotive components are flagged as contingent on completion of the full Interim Agreement.

Malaysia replaced its four-decade-old Promotion of Investments Act (PIA) 1986 manufacturing-incentive regime with the New Incentive Framework (NIF), effective 1 March 2026. Applications under PIA 1986 closed at 15:00 MYT on 28 February 2026; post-March applications are evaluated under the outcome-based National Investment Aspirations (NIA) Scorecard across six economic-outcome pillars. Companies choose between two mutually exclusive incentive options — a special corporate tax rate or an investment tax allowance — aligned with the Global Minimum Tax environment. A services-sector phase is scheduled for Q2 2026.

On 27 January 2026 the European Union and India announced the conclusion of negotiations on a comprehensive Free Trade Agreement at the EU-India summit hosted at Hyderabad House in New Delhi, attended by PM Narendra Modi, Commission President Ursula von der Leyen and Council President António Costa. The deal — described by both leaders as the "mother of all deals" — covers ~25% of world GDP and ~2 billion people. The EU eliminates duties on 91% of tariff lines (covering 99.3% of bilateral trade by value); India eliminates duties on 86% of lines (covering 96.6% by value). Headline cuts include Indian tariffs on EU wines (150% → 75% at entry into force, falling to 20%), olive oil (45% → 0% over five years) and processed agri-food (up to 50% eliminated); EU tariffs are reduced/eliminated on Indian textiles, leather/footwear, gems and jewelry, marine products, tea, coffee, spices and certain agricultural and steel products. The agreement still requires Council adoption, European Parliament consent and approval by India's Union Council of Ministers; entry into force is expected in early 2027. Companion instruments concluded at the same summit include an EU-India Security and Defence Partnership and a Mobility and Migration Agreement.

On 16 January 2026 the Saudi Council of Ministers, via Cabinet Decision No. 468/1447 (issued 30 December 2025 / 9 Rajab 1447H), published in the Umm Al-Qura Official Gazette four sets of implementing regulations governing the King Abdullah Economic City (KAEC), Ras Al-Khair, Jazan, and Cloud Computing & IT Special Economic Zones. The regulations entered into force on 16 April 2026 (90 days after gazette publication) and operationalise the SEZ framework first launched by ECZA in April 2023. Each zone has its own standalone framework but they share a common headline tax package: 5% corporate income tax for up to 20 years, zero VAT on intra-SEZ and SEZ-import flows, customs-duty suspension on qualifying imports, withholding-tax exemption on dividends and approved cross-border payments, and exemption from key provisions of the Saudi Companies Law, Commercial Register Law, and Trade Names Law. KAEC focuses on advanced manufacturing, automotive, consumer goods, ICT and pharmaceuticals; Ras Al-Khair targets shipbuilding, offshore rigs and MRO; Jazan covers food processing, metals conversion and logistics for Africa-bound trade; the Cloud Computing SEZ is a virtual zone (data centres can sit anywhere in KSA, headquarters must be in Riyadh) for cloud and AI-compute workloads. The package is the operational implementation layer for the 2024 Investment Law and a core Vision 2030 FDI-attraction instrument.

On 14 January 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 titled "Adjusting Imports of Processed Critical Minerals and Their Derivative Products into the United States". Unlike the parallel 14 January 2026 semiconductor proclamation and the subsequent April 2026 pharmaceutical proclamation, the PCMDP proclamation does NOT immediately impose tariffs. Instead it directs the Secretary of Commerce and the U.S. Trade Representative to jointly negotiate bilateral and plurilateral supply agreements with trading partners, with an initial 180-day status report due 13 July 2026. The proclamation reserves residual authority to impose tariffs if negotiations fail or prove ineffective, and explicitly contemplates "price floors" on PCMDP imports as a negotiated instrument.

At its 30 December 2025 regular session, Iraq's Council of Ministers, chaired by Prime Minister Mohammed Shia' Al-Sudani, approved two additional customs duties on imports from all countries of origin: a 40% additional duty on medical and industrial oxygen (gaseous and liquid forms), in effect for four years, and a 30% additional duty on imported yogurt (laban rayeb) and liquid milk. Both measures were framed as protecting domestic pharmaceutical/ industrial-gas production and local dairy manufacturing respectively, and take effect 120 days after issuance (29 April 2026) to give importers an adjustment window. Global Trade Alert logs the dairy duty as principally affecting Germany, Saudi Arabia and Türkiye as leading supplier origins, though the measure itself is non-discriminatory (applies to all origins).

On 19 December 2025 the Swiss Federal Assembly adopted in final vote the Federal Act on the Screening of Foreign Investments (Bundesgesetz über die Prüfung ausländischer Investitionen, Investitionsprüfgesetz / IPG; popularly the "Lex China", parliamentary business 22.035). The Act introduces Switzerland's first general ex-ante FDI-screening regime: acquisitions of control over Swiss companies active in security-critical sectors by foreign state-controlled investors require prior approval by SECO, with escalation to the Federal Council. The optional- referendum window runs until 17 April 2026; entry into force is not expected before 2027 once implementing ordinances are adopted. Critical sectors named in the Act include military and dual-use goods, electricity grids and generation, water supply, pharma and health, telecommunications, transport infrastructure and financial-market infrastructure.

Section 851 of the FY 2026 National Defense Authorization Act (P.L. 119-60), signed December 18, 2025, prohibits US federal agencies from procuring biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), and bars federal contractors from using such equipment/services in work performed under federal contracts, grants, or loans. The final enacted text ties initial BCC designations to DoD's existing §1260H Chinese-military-company list (which currently includes BGI and MGI, but not WuXi AppTec or WuXi Biologics) and directs OMB to designate additional BCCs within one year of enactment; operational prohibitions activate 60-90 days after FAR revision, with a five-year grandfather period for pre-existing contracts — enforcement is expected to begin in 2027-28. The legislation is the successor to H.R.8333 (118th Congress, House-passed September 2024 but stalled in the Senate before adjournment) and represents the first enacted US federal-procurement biotech-supply-chain-resilience statute.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

In the early hours of 11 December 2025 the Council of the EU and the European Parliament reached provisional political agreement in trilogue on the "EU Pharma Package" — the revised pharmaceutical Regulation (COM 2023/0131) and Directive (COM 2023/0132) — the most significant overhaul of EU pharmaceutical legislation in over two decades. The package replaces Directive 2001/83/EC (Community Code on medicinal products for human use) and Regulation (EC) 726/2004 (the EMA Regulation), and consolidates the orphan-medicine (Regulation 141/2000) and pediatric-medicine regulations into a single framework. Headline provisions: (i) a new "8+1(+1)(+1)" IP-incentive architecture — 8 years of regulatory data protection plus 1 year of market protection, with up to two additional 12-month extensions for products addressing unmet medical need or new active substances meeting comparative-trial conditions, capped at 11 years total; (ii) an EU-wide list of critical medicines under enhanced governance via the Medicines Shortages Steering Group (MSSG) and an EMA "list of critical shortages in the EU"; (iii) mandatory shortage-prevention plans on marketing-authorisation holders for prescription medicines and Commission-designated products; (iv) modernisation of clinical-trial requirements, environmental-risk assessment, antimicrobial stewardship, and a transferable-exclusivity-voucher (TEV) regime to incentivise novel antibiotic R&D. The COREPER I committee endorsed the compromise text on 6 March 2026 and final adoption by Parliament and Council is expected during summer 2026, with the regulatory framework becoming applicable in 2028.

On 9 December 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) issued the December 2025 batch expansion of its Mandatory List — a binding instrument requiring government entities, state-owned enterprises, and sub-contractors to source listed products exclusively from Saudi domestic manufacturers meeting the LCGPA-defined local-content threshold. The December 2025 expansion brings the list to approximately 1,444 national products across 16 sectors, effective 1 March 2026, with LCGPA targeting a total of approximately 2,000 products by end-2026. The Mandatory List operationalises the demand-side layer of Saudi Arabia's Vision 2030 / National Industrial Strategy (NIS) industrial-policy stack, directly restricting foreign-supplier access to Saudi annual government-procurement budgets estimated at SAR 500 billion+ across central government, Aramco, PIF-portfolio entities, Ma'aden, SEC, STC, Saudi Post, and Saudi Railway.

On 13 November 2025, the United States and the Republic of Korea released a Joint Fact Sheet reaffirming the July 2025 announcement of the Korea Strategic Trade and Investment Deal — the first standalone US-Korea trade-and-investment agreement since the 2012 KORUS FTA. USTR issued the implementing Federal Register notice (90 FR 55964, Notice 2025-21940) on 3 December 2025, effective 4 December 2025, with retroactive HTSUS application to 1 November 2025 for autos and auto parts and to 14 November 2025 for reciprocal-tariff goods, timber, lumber, derivatives, and certain aircraft and aircraft parts. On the US tariff side: (i) the country-specific IEEPA reciprocal tariff on Korean originating goods is set at the higher of the KORUS FTA / MFN rate or 15% (parallel to the Japan and EU framework deals); (ii) the Section 232 tariffs on autos, auto parts, timber, lumber and wood derivatives are reduced to 15% (no incremental duty when the pre-existing KORUS/MFN rate already meets or exceeds 15%); (iii) Korean exports of qualifying goods on the Potential Tariff Adjustments for Aligned Partners (PTAAP) list are exempt from reciprocal tariffs (covering generic pharmaceuticals and unavailable natural resources); (iv) Section 232 pharmaceuticals capped at 15%; semiconductors granted MFN-style "no less favourable" treatment in any future sectoral deal. On the investment side, Korea commits to a USD 350bn package: USD 150bn into US shipbuilding ("Approved Investments") plus USD 200bn into US strategic industries via a separate Strategic Investments MOU, with annual currency-funding cap of USD 20bn. Non-tariff commitments include streamlined US biotech approvals on the Korean side, US meat and cheese market access, fair treatment for US digital services, removal of Korea's 50,000-unit cap on US vehicles meeting FMVSS, and joint WTO support for the moratorium on customs duties on electronic transmissions.

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

Bangladesh's Council of Advisers, chaired by Chief Adviser Prof. Muhammad Yunus, approved the National Logistics Policy 2025 on 6 November 2025 at its 47th meeting, replacing the annulled 2024 Awami League-era logistics policy. The framework spans 11 chapters and establishes a technology-driven, integrated, sustainable logistics ecosystem aimed at positioning Bangladesh as a leading regional trade and logistics hub by 2050. Two-tier governance architecture: a National Logistics Council (led by the Chief Adviser) for top-level coordination, and a National Logistics Development and Coordination Committee (led by the Chief Adviser's Principal Secretary) for implementation oversight across multimodal hubs, economic zones, international corridors, airports, river ports, sea ports, and land ports.

The UK Office for Life Sciences (OLS) launched the Life Sciences Large Investment Portfolio (LSLIP), a subsidy scheme worth up to GBP 570 million running from implementation in November 2025 to March 2030. The scheme provides direct grants, capped at GBP 130 million per award, to UK-registered private-sector companies committing to invest GBP 250 million or more over three years in domestic manufacturing or commercial R&D across three subsectors: human medicines (APIs and finished products), medical diagnostics, and MedTech. The scheme was referred to the CMA's Subsidy Advice Unit on 21 August 2025, which published its advisory report on 2 October 2025 ahead of the scheme's launch.

China's State Council promulgated Order No. 818 on 28 September 2025 (effective 1 May 2026), establishing a comprehensive dual-track regulatory framework for biomedical new technologies — defined as techniques operating at the cellular or molecular level not yet clinically applied in China, covering cell therapy, gene editing, CAR-T, stem-cell, xenotransplantation, brain-computer interfaces, and nucleic-acid therapies. The regulation creates two parallel pathways: a traditional NMPA drug/device registration route and a new NHC-supervised clinical-research-to-commercialization track applicable to highly personalised or rare-disease therapies meeting staged safety and efficacy thresholds. Commercialisation under the NHC track is initially restricted to accredited Grade-3A medical institutions without full NMPA marketing approval, potentially accelerating patient access for qualifying technologies by 5–8 years relative to the standard registration pathway.

On 26 September 2025, Japan's Minister of Finance Katsunobu Kato announced the establishment of the Japan Strategic Investment Facility, a JBIC-administered financing vehicle operationalising the USD 550bn investment pledge from the July 2025 US-Japan tariff and investment agreement. The facility launched 1 October 2025 and runs through March 2029, supporting the overseas expansion of Japanese companies across nine economic-security sectors: semiconductors, pharmaceuticals, steel, shipbuilding, critical minerals, aviation, energy, automobiles, and AI/quantum technology. Funding draws on three sources — dollar-denominated JBIC bonds, yen-denominated Japanese government loans to JBIC, and a "supplemental" transfer from Japan's USD 1.324tn foreign-currency reserves — with private-sector loans and NEXI-backed loan guarantees supplementing JBIC's own financing.

President Trump signed Executive Order 14345 on 4 September 2025, implementing the July 2025 US-Japan trade agreement by setting a 15% baseline ad-valorem tariff on nearly all Japanese goods — raising any Column 1 (MFN) duty rate below 15% up to that floor, including on agricultural lines such as cereals, vegetables, and fruits and nuts. The modification applies retroactively to Japanese products entered for consumption on or after 12:01 a.m. EDT, 7 August 2025, and supersedes the higher 24% country-specific reciprocal rate Japan faced under the April 2025 "Liberation Day" schedule. Aerospace products are exempted entirely, autos/auto parts receive the same 15% treatment (down from a separate 25% Section 232 rate), and Japan committed to $550bn in US investment and $8bn/year in additional US agricultural purchases (rice, corn, soybeans, fertilizer, bioethanol) as consideration.

South Korea's National Assembly passed an amendment to the Korea Development Bank (KDB) Act on 2025-08-27 (428th session, 3rd plenary sitting, 164-1 with 164 votes in favour of 165 cast), raising KDB's statutory capital ceiling from KRW 30 trillion to KRW 45 trillion and creating a new "Advanced Strategic Industry Fund" inside KDB. The fund is capitalised at KRW 50 trillion or more over five years via low-rate government-guaranteed bonds and is earmarked for the ten officially designated advanced strategic industries (AI, semiconductors, bio/vaccines, defense, robotics, hydrogen, secondary batteries, displays, future mobility) via cheap loans and equity investment. KDB intends to use the fund as seed capital for a wider "National Growth Fund" that blends in private and pension capital to reach KRW 100 trillion+ in total strategic-industry financing over five years.

Act L of 2025 (2025. évi L. törvény) is the Hungarian National Assembly statute that elevates a set of war-emergency government decrees — including the foreign-investment screening regime previously embedded in Government Decree 561/2022 — to permanent statutory level. Promulgated in Magyar Közlöny and entered into force on 19 August 2025, the Act preserves Hungary's "Second Regime" of FDI screening operating in parallel with the General Regime (which implements EU Reg 2019/452 since 2019). The Second Regime applies to a broad set of strategic sectors — energy, transport, communications, telecoms, pharmaceuticals, food processing, defence, financial services and healthcare — and requires approval from the Minister of National Economy for qualifying acquisitions (direct or indirect majority, ≥5% interest, ≥3% in listed companies, or ownership/operation of strategic infrastructure) where transaction value reaches HUF 350 million (~EUR 890,000). Notification is due within 10 days of signing; the MoE originally had 30 business days (extendable +15 calendar days). The Act also entrenches the Hungarian state right of first refusal on photovoltaic generation companies (NACE 35.11'08, excluding sub-50 kVA household installations), exercised through MNV Zrt. The Special Regime is structurally distinct from the General Regime and represents Hungary's peer to the German AWG §§55-62, French Décret 2014-479, Dutch Wet Vifo, and Italian Golden Power. Amended by Act XCIII of 2025 (in force 17 December 2025), which extended the MoE screening deadline to 45 business days and excluded bank-financing security arrangements from notification.

On 13 August 2025 President Trump signed an Executive Order ("Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve", Federal Register Doc. 2025-15823, published 19 August 2025) directing the HHS Assistant Secretary for Preparedness and Response (ASPR) to refill and operationalise the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). Within 30 days, ASPR must compile an initial list of 26 essential drugs, account for available funding, and acquire and maintain a six-month supply of the corresponding APIs. Within 90 days, ASPR must deliver an expanded list of up to 86 essential medicines and medical countermeasures plus a plan to source those APIs from domestic manufacturers, and within 120 days (subject to appropriations) ready the existing SAPIR repository and submit a proposal and cost estimate for opening a second repository. The order prioritises domestically manufactured APIs in federal procurement and reserve build-out and directs interagency coordination across HHS/ASPR, FDA, DoD (Industrial Base Fund / Defense Production Act Title III), and the Department of Commerce.

On 27 July 2025, President Trump and European Commission President Ursula von der Leyen reached political agreement at Turnberry, Scotland, on a Framework Agreement on Reciprocal, Fair and Balanced Trade. The framework was formalised in a Joint Statement published on 21 August 2025 by the White House and DG TRADE. The deal establishes a 15% all-inclusive (MFN + Section 232) US tariff ceiling on the vast majority of EU originating goods — including autos, pharmaceuticals, semiconductors, lumber, and chemicals — replacing the threatened 20-30% reciprocal tariff trajectory under EO 14257 (April 2025). Steel and aluminium are excluded from the 15% ceiling and remain at the 50% Section 232 rate pending negotiation of a quota solution. In return, the EU commits to: (i) eliminate tariffs on all US industrial goods, (ii) preferential market access for a wide range of US agricultural and seafood products, (iii) suspension of its rebalancing countermeasures under Reg 2025/778 (suspension effective 7 August 2025), (iv) expected energy offtake of $750bn (LNG, oil, nuclear) through 2028, (v) at least $40bn in US AI chip purchases, and (vi) facilitation of $600bn in additional EU corporate investment into the US through 2028. Effective from 1 September 2025, the US applies MFN-only treatment (no 15% top-up) to: aircraft and parts, generic pharmaceuticals and ingredients, chemical precursors, cork, and certain unavailable natural resources. The framework is not legally binding but anchors the bilateral architecture; it is the largest-economy ART-programme deal alongside US-UK, US-Japan, US-Korea, US-Taiwan, and US-Indonesia.

The Polish Sejm passed the Act of 9 July 2025 amending the Act of 24 July 2015 on the Control of Certain Investments, signed by the President on 21 July 2025 and effective 24 July 2025. The amendment removes the time-limited "Specialised Rules" tier (introduced in 2020 under the Anti-COVID Shield) and makes Poland's FDI screening regime permanent. Review competence is transferred from the President of UOKiK (the competition authority) to the minister responsible for economic affairs (currently the Minister of Finance and Economy), and a new trigger covering "an international situation distorting the market or competition" is added alongside the existing public-order, security and health grounds.

Minister of Trade Regulation No. 20 of 2025, signed by Minister Budi Santoso on 30 June 2025 and effective 29 August 2025 (60 days after promulgation), reorganises Indonesia's import regime for chemicals, Hazardous Materials (B2), and a defined set of mining and energy inputs. The regulation revokes Permendag 8/2024 and requires holders of designated importer status (Importir Terdaftar / Importir Produsen) to secure an Import Approval (Persetujuan Impor) plus a post-arrival Surveyor Report (Laporan Surveyor) for an eleven-cluster commodity bundle including lubricant raw materials, cement clinker and cement, rough diamonds, non-pharmaceutical precursors, crude oil and natural gas, nitrocellulose, commercial-industrial explosives, ozone-depleting substances, hydrofluorocarbons, B2, and certain other chemicals (BKT). It is one of nine commodity-cluster Permendags issued the same day under the Prabowo administration's umbrella import-policy deregulation package.

On 2025-06-02 Mexico published a presidential decree ("DECRETO por el que se fomenta la inversión en territorio nacional, para fortalecer el desarrollo de la industria farmacéutica y la producción de insumos para la salud; así como el desarrollo de investigación científica nacional") in the Diario Oficial de la Federación, effective 2025-06-03. Starting with fiscal-year 2026 consolidated federal purchases of medicines, health inputs and medical devices (for 2027 delivery), the Secretaría de Salud will apply a points-and-percentage evaluation scheme that favors bidders holding productive investment or infrastructure (plants, laboratories, warehouses) in Mexico, or that conduct scientific research domestically. A tri-ministry Promotion Committee (Health, Economy, and the Anticorruption/Public Function ministry) will vet investment commitments, and the decree directs the Secretaría de Salud to issue implementing guidelines within 90 calendar days of publication.

On 28 May 2025, Brazilian President Lula launched "Chamada Nordeste" in Salgueiro (Pernambuco) — a BRL 10 billion (~USD 1.8bn) public call for structuring investment projects in the nine Northeast states, run jointly by BNDES, Banco do Brasil, Caixa Econômica Federal, Banco do Nordeste (BNB) and Finep, with technical support from Sudene and the Northeast Consortium. It is the largest project call ever run for the region and sits under the federal Nova Indústria Brasil (NIB) industrial-policy umbrella. Eligible business plans (minimum BRL 10 million) cover storage/renewable energy, bioeconomy with a pharmaceuticals focus, green hydrogen, green data centers and the automotive/agricultural-machinery sector, financed via a combination of credit lines, non-reimbursable economic subsidies and equity participation; the proposal deadline was 15 September 2025. Demand vastly exceeded supply: the call drew 245 proposals totalling roughly BRL 127.8 billion — nearly 13 times the initial BRL 10bn envelope — before BNDES approved 189 projects worth BRL 113 billion in follow-on selection rounds.

Japan's National Diet passed a partial amendment to the Pharmaceutical and Medical Device Act (PMD Act / 薬機法) on May 14, 2025, promulgated as Law No. 37 of 2025 on May 21. The amendment requires every Marketing Authorization Holder (MAH) to designate a Supply System Manager responsible for reporting supply disruptions to MHLW, and grants MHLW authority to order replacement of key quality personnel when systemic deficiencies are found. It also reforms GMP oversight to a risk-based inspection model and expands the conditional-approval pathway for rare disease and paediatric drugs. Enforcement is staggered across three tranches: November 2025, May 2026, and final full implementation by May 2027.

President Trump signed Executive Order 14273, "Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients", on 12 May 2025. The EO directs HHS, USTR, and Commerce to pursue mechanisms (negotiation targets, importation pathways, and trade-policy levers) to bring the prices Americans pay for innovative prescription drugs into alignment with the *lowest* prices paid by other comparably-developed nations — the "most-favored-nation" (MFN) benchmark. Unlike the Biden-era Inflation Reduction Act drug-price-negotiation provisions (which apply to a handful of Medicare Part D drugs), the EO applies pressure across the broader pharmaceutical pricing surface. As of April 2026, 17 major pharmaceutical manufacturers (incl. Eli Lilly, Pfizer, Bristol-Myers Squibb, AbbVie, Merck, AstraZeneca, Regeneron) have signed bilateral agreements bringing US drug prices toward the international- benchmark level for selected medications.

On 8 May 2025, President Trump and UK Prime Minister Starmer announced the General Terms of the US-UK Economic Prosperity Deal (EPD), the first bilateral framework arrangement of the second Trump administration and the template instrument for subsequent US bilateral framework deals (US-Japan, US-Indonesia, US-Argentina, US-Korea, US-EU). The framework was implemented on 23 June 2025 via Executive Order 14309 (Federal Register doc 2025-11473). Key US concessions: a 100,000-vehicle annual TRQ for UK autos at a 10% combined rate (7.5% + 2.5% MFN, vs. 27.5% Section 232 default); aerospace tariff reduction back to MFN rates; authority delegated to Commerce/USTR to establish UK-only TRQs for steel and aluminum (in lieu of the 50% Section 232 global rate). Key UK concessions: 13,000 mt duty-free beef quota (with 20% tariff removal on the existing 1,000 mt WTO quota); 1.4 billion litre duty-free ethanol quota; commitment to negotiate non-tariff barrier reductions and supply-chain security alignment. The 10% IEEPA "reciprocal" baseline tariff on most other UK goods is preserved by the EPD.

On 11 March 2025 the European Commission published its proposal for a Critical Medicines Act (CMA), pillar of the broader EU pharmaceutical-resilience agenda alongside the EU Critical Raw Materials Act (filed: 2024-05-23-eu-crma-entry-into-force) and the IRA-style industrial-policy stack. The proposal targets supply security of an EU "Union List" of critical medicines (antibiotics, anti-thrombotics, oncology, cardiovascular, insulin, painkillers) by introducing four mechanisms: (1) Strategic Project status with expedited funding access for critical-medicine manufacturing or active-substance production; (2) public-procurement preferences favouring resilient supply chains and — in defined cases — EU-based production; (3) collaborative cross-Member-State procurement to address fragmented small markets; (4) state-aid framework guidance + international-partnership diversification to reduce single-country (often China-routed) API dependency.

On 1 February 2025, Finance Minister Nirmala Sitharaman announced the National Manufacturing Mission (NMM) in the Union Budget 2025-26 as a horizontal umbrella framework extending the 2014 "Make in India" architecture across small, medium and large industries. The mission rests on five focal areas: (i) ease and cost of doing business; (ii) a future-ready workforce for in-demand jobs; (iii) a vibrant and dynamic MSME sector; (iv) availability of technology; and (v) quality manufacturing. It will deliver policy support, execution roadmaps, and a governance/monitoring framework binding central ministries with states. NMM specifically commits to building a clean-tech manufacturing ecosystem with explicit coverage of solar PV cells, EV batteries, motors and controllers, electrolysers, wind turbines, very-high-voltage transmission equipment, and grid-scale batteries — i.e., the full hardware stack for India's Panchamrit (500 GW non-fossil by 2030), FAME-III EV ramp, and National Green Hydrogen Mission. NMM is the first horizontal Indian manufacturing-mission instrument in the IPTM register; existing IND entries are sector-specific PLIs (electronics, batteries, steel, semiconductors) and the National Critical Mineral Mission. Operational rollout flows through subsequent Cabinet-level scheme approvals (e.g. Biopharma SHAKTI ₹10,000 cr, Chemical Parks ₹600 cr in BE 2026-27); the mission itself does not carry a single headline outlay because it is the framework rather than an instrument.

On 9 January 2025, Prime Minister and Minister of Foreign Affairs HE Sheikh Mohammed bin Abdulrahman bin Jassim Al Thani unveiled the Qatar National Manufacturing Strategy 2024–2030 alongside the Ministry of Commerce and Industry (MoCI) sectoral strategy at the Qatar National Convention Centre. The manufacturing strategy targets raising sectoral value-add to QAR 70.5bn (~USD 19.4bn), lifting non-hydrocarbon industrial exports above QAR 49bn (~USD 13.5bn), attracting annual industrial investment of QAR 2.75bn (~USD 755m), and placing Qatar among the world's top 40 economies in the UNIDO Competitiveness Industrial Performance index by 2030. It is built on four transformative pillars: shift to smart and green manufacturing, R&D-led productivity uplift, alignment of education and training with industrial demand, and expansion of Qatari workforce participation (Qatarisation), delivered through 15 strategic initiatives and 60 projects.

Bahrain's Ministry of Industry and Commerce issued Decision No. 53 of 2024, amending the conditions governing foreign ownership in commercial activities, effective 18 October 2024. The reform permits 100% foreign ownership of commercial enterprises — including wholesale and retail trade and authorized distribution — without a mandatory Bahraini local partner, where the foreign company operates in at least 10 countries or generates annual revenue above EUR 750 million. It simultaneously reduces the minimum capital requirement for foreign-owned companies in Bahrain by 95%, from BHD 2,000,000 (~EUR 5m) to BHD 100,000 (~EUR 240,000), materially expanding the addressable foreign-investor pool to mid-market commercial enterprises.

Moldova's Cabinet of Ministers approved Government Decision HG 280/2024 on 17 April 2024, adopting the National Industrial Development Programme 2024-2028 (Programul Național de Dezvoltare Industrială pentru 2024-2028). The programme sets a manufacturing GDP-share target from 8.2% (2023 baseline) to 11.5% by 2028 and at least 25% industrial-production volume growth, with priority given to six sectors: electronics, chemical-pharmaceutical, auto-components, textiles, construction materials, and food industry. It operationalises Moldova's EU-candidacy industrial-alignment commitments under the EU Reform and Growth Facility (€1.9bn 2024-2027 envelope) and the national development strategy European Moldova 2030. A Regional State Aid Scheme for Investments — launched January 2025 under HG 280/2024 — provides grants covering up to 60% (large/medium enterprises) or 75% (small enterprises) of qualifying investments above a MDL 10 million threshold, combined with a 75% income-tax exemption, targeting approximately 150 enterprises with ~€100 million in total state aid through 2034.

On 21 March 2024, President William Ruto formally launched Kenya's Fourth Medium Term Plan 2023-2027 (MTP IV) at State House Nairobi, the final five-year implementation plan under the Kenya Vision 2030 blueprint. MTP IV is the operational vehicle for the Bottom-Up Economic Transformation Agenda (BETA), the Ruto administration's foundational industrial-policy and value-chain framework. The plan organises Kenya's industrial-policy push around five core BETA pillars and nine value chains: agro-processing (incl. edible-oil crops, leather, dairy, tea), textiles and apparel, housing and settlement, healthcare and pharmaceuticals, digital superhighway and creative economy, manufacturing (incl. automotive and EV motorcycle and vehicle assembly), MSME and cooperative sector strengthening, and blue-economy/natural-resource value addition. Implementation is anchored in County Aggregation and Industrial Parks (CAIPs) across all 47 counties and in the County Integrated Development Plans (CIDPs). MTP IV is the umbrella framework shaping Kenya's domestic industrial-incentive architecture, foreign-investment priorities, and AfCFTA positioning over 2023-2027. Subsequent sectoral instruments — including the Mining Royalty Collection and Management Regulations 2024 — operate within this policy perimeter. This is the first KE foundational industrial-policy filing in the register.

Three-year export-promotion policy issued by the Bangladesh Ministry of Commerce on 25 February 2024 covering FY2024-25 through FY2026-27. Sets a $110bn merchandise+services export target by FY2026-27 (vs. ~$56bn FY2023-24 base), restructures the cash-incentive regime, and designates "highest priority" and "special development" sectors including ready-made garments, leather, jute, ICT, pharmaceuticals, agro-processing, light engineering, and plastics. Explicitly designed as the transition framework for navigating Bangladesh's LDC graduation (effective 24 November 2026), at which point the country will lose EU Everything-But-Arms duty-free access and face an estimated 10% average MFN tariff on EU exports.

Switzerland's Federal Council promulgated the Verordnung über die Mindestbesteuerung grosser Unternehmensgruppen (Mindestbesteuerungsverordnung, MindStV; French: OIMin), SR 642.161, AS 2023 841, on 22 December 2023, with effect from 1 January 2024. The ordinance enacts a 15% Qualified Domestic Minimum Top-up Tax (QDMTT — Ergänzungssteuer) on Swiss constituent entities of MNE groups with consolidated annual revenue ≥ EUR 750 million, enacted under the temporary constitutional authority granted by Swiss voters in a popular referendum on 18 June 2023 (78.5% yes, Art. 129a BV). The Income Inclusion Rule (IIR) and Undertaxed Profits Rule (UTPR) were deliberately deferred to subsequent ordinance amendments, targeting FY 2025 phasing. The Swiss Federal Tax Administration (ESTV / AFC) is the administering authority; first QDMTT returns and GloBE Information Returns due 30 June 2026.

Ireland's Screening of Third Country Transactions Act 2023 (Act No. 28 of 2023), signed into law on 31 October 2023 and commenced on 6 January 2025 via S.I. No. 651 of 2024, establishes Ireland's first-ever mandatory inbound FDI screening regime. The Act empowers the Minister for Enterprise, Tourism and Employment to assess, condition, or prohibit transactions by third-country investors (non-EU/EEA/Switzerland) exceeding a EUR 2 million cumulative threshold in targets operating across critical infrastructure, critical technologies, dual-use items, supply of critical inputs, sensitive personal data, and media freedom. A 90-day standstill period applies during Ministerial determination, with criminal sanctions and transaction-voiding powers available for non-compliance.

Malaysia's New Industrial Master Plan 2030 (NIMP 2030) is the fourth-edition national industrial master plan launched on 1 September 2023 by Prime Minister Anwar Ibrahim under the Ministry of Investment, Trade and Industry (MITI). Spanning seven years to 2030, NIMP 2030 adopts a mission-based approach with 4 missions, 21 strategies and 62 action plans, mobilising an RM95bn investment envelope (predominantly private-sector capital channelled through private equity and the capital markets). The plan targets a step-change in manufacturing-sector economic complexity, deeper local-industry linkages and expanded participation in global supply chains, with explicit numerical targets for the manufacturing sector's GDP contribution and annual growth by 2030.

Directive (EU) 2022/2555 of the European Parliament and of the Council of 14 December 2022 on measures for a high common level of cybersecurity across the Union (NIS 2 Directive), published OJ L 333, 27 December 2022, entered into force 16 January 2023. NIS2 repeals and substantially expands the 2016 NIS1 Directive (2016/1148), extending the scope from ~7 sectors to 18 enumerated essential and important sectors, imposing binding cybersecurity risk- management and incident-reporting obligations on covered entities, introducing board-level management accountability, and mandating Member State transposition by 17 October 2024. NIS2 is the structural EU statutory anchor for national cybersecurity frameworks across the bloc, operating alongside DORA (Reg 2022/2554) for financial-sector digital resilience and CRA (Reg 2024/2847) for product cybersecurity.